Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
[1] [2] Secondary findings from clinical trials suggest potential benefits on blood pressure and liver fat content, though these are not FDA-approved indications
The supplement is classified in our slimming and weight loss product category
TNF-alpha was reduced by 38 percent, a pro-inflammatory enzyme called iNOS was reduced by 43 percent, and the anti-inflammatory cytokine IL-4 increased by 2.55-fold [2]
Following an update to its Summary of Product Characteristics (SmPC) in April 2026, the MHRA now indicates that Mounjaro (tirzepatide) could be considered for use during breastfeeding a notable shift from earlier caution
charged with receipt of child sexual abuse materials in court | FOX 5 AT 4AM video Former Glen Haven Elementary teacher faces trial in assault case video TOP STORIES | Flash flood warnings in DC area
MHRA reminds healthcare professionals to advise patients of the side effects of GLP-1 agonists and to report misuse
